Preliminary data on the variant suggest it does not trigger more severe illness than previous variants
Fourth COVID-19 Shot Beneficial in Patients With Autoimmune Rheumatic Diseases
Fourth dose reduces risk for SARS-CoV-2 for patients with systemic autoimmune rheumatic diseases using DMARDs
Fluvoxamine Does Not Shorten Duration of COVID-19 Symptoms
Findings observed among adults with mild or moderate COVID-19